Publication: GLI1 expression is an important prognostic factor that contributes to the poor prognosis of rhabdomyosarcoma
Authors
Wang, Yuanyuan ; Sun, Chao ; Jiang, Jinfang ; Xie, Yuwen ; Li, Bingcheng ; Cui, Xiaobin ; Chen, Yunzhao ; Liu, Chunxia ; Li, Feng
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂa Celular e HistologĂa
publication.page.editor
publication.page.department
DOI
10.14670/HH-11-682
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The GLI1 and MDM2 genes are amplified or
exhibit copy number gains in rhabdomyosarcoma
(RMS). Here, we used immunohistochemistry to
determine the relationships between GLI1 and MDM2
protein expression and several clinicopathological
variables of RMS. GLI1 and MDM2-positivity rates
were 61.36% and 13.64%, respectively. GLI1 expression
correlated with presence of the PAX3-FOXO1 fusion
gene (P=0.040) and lymph node metastasis (P=0.034),
and a significant association was found between GLI1
expression and overall survival (OS) (P=0.008).
However, there was no association between MDM2
expression and any of the clinicopathological parameters
or OS. Thus, GLI1 may be a biomarker of poor
prognosis in RMS patients, and could itself be a
therapeutic target. This contrasts with the apparent lack
of clinical importance of MDM2 in RMS pathology, at
least in the cohorts we examined.
publication.page.subject
Citation
Histology and Histopathology, vol.31, nÂş3, (2016)
item.page.embargo
Ir a EstadĂsticas
Este Ătem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/